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ABSTRACT 
Ischaemic stroke and TIA, together labelled as Ischaemic Cerebrovascular Disease (ICVD), 
is a heterogeneous, complex disorder with great impact on morbidity and mortality 
worldwide. Genetic predisposition and environmental factors interact and confer 
susceptibility to different pathologies that are associated with increased ICVD risk. The 
most common aetiological mechanisms include large vessel atherosclerosis, sources of 
cardioembolism and small vessel disease. Distinct pathologies underlying ICVD may occur 
alone or co-exist in various combinations where their causal relation to the actual ischaemic 
event is difficult to determine. The TOAST system has been the most widely accepted 
classification approach that assigns patients in one of the three main aetiological subtypes, 
if evidence for a causal relation exists, or to unknown if the investigation has been 
inconclusive. The ASCO system has recently suggested a different approach by which all 
the three pathologies are evaluated and graded for the likelihood to have a causative 
association with the ischaemic event. Related comorbidities, risk factor profile, treatment 
choices and prognosis differ in each aetiological subtype of ICVD, yet with several 
overlapping features. One common aspect, though with diverse pathways, involves 
inflammatory mechanisms that contribute to the initiation and progress of pathologies 
mediating ICVD, and have an ambiguous role in brain tissue damage during cerebral 
ischaemia. Moreover, factors of coagulation and metabolism have been suggested to 
correlate with aetiological subtypes of ICVD and to serve as predictors of long-term 
disability. The purpose of this project was to investigate the role of genetic and blood-based 
biomarkers in ICVD susceptibility, aetiology and prognosis.  
 
Ischaemic stroke and TIA patients admitted over different periods in the stroke-unit of 
Karolinska University Hospital in Huddinge, as well as healthy individuals comprised the 
population of our studies. In the first, case-control study on delta32 mutation that abolishes 
CCR5 from cell surface, we found that the presence of the mutated allele was less common 
in patients with cardioembolic ICVD compared to those with other aetiological subtypes. 
Hence, we assumed that CCR5 might play a role in predisposition to cardiac conditions that 
confer increased embolic risk. In the subsequent studies we investigated the association of 
blood-borne markers with aetiological subtypes and long-term survival in ICVD. Our 
results imply that increased levels of glucose, white blood cell count and fibrinogen, as well 
as low levels of cholesterol on admission, may be associated with poorer long-term survival 
after stroke and TIA. Investigation of aetiological phenotypes according to TOAST and 
ASCO showed very good agreement between the two classification systems in all 
subgroups except for large vessel stroke where the matching was good. Long-term survival 
was higher in patients with small vessel stroke and poorer in patients with incomplete 
work-up followed by cardioembolic and cryptogenic aetiology. 
 
Overall, our findings indicate that molecules involved in inflammation and metabolism 
may play a role in the pathology and prognosis of ICVD. We also addressed the issue of 
aetiological classification in stroke, and how different approaches may improve research 
accomplishments. Our studies are not designed to serve as sources of conclusions on causal 
mechanisms associated with disease occurrence and outcome. Future studies on larger, 
well-described populations are needed in order to clarify the processes involved in different 
aetiopathogeneses of stroke.
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